摘要
目的:探讨黄芪多糖(astragalus polysaccharide,APS)体外是否具有化疗增敏作用及其可能机制。方法:用MTT法检测APS协同化疗药对H22/ADM敏感性、用流式细胞术、免疫印迹法和荧光定量PCR进一步检测其P-糖蛋白(P-GP)功能、P-GP和mdr1mRNA表达。结果:在终浓度0.8～500μg.mL-1范围内APS可降低阿霉素(adriamycin,ADM)、5-氟脲嘧啶(5-fluorouracil,5-Fu)、顺铂(cisplatin,DDP)、依托泊苷(etoposide,VP-16)对H22/ADM的IC50值,使其Rho-123潴留增多,增加荧光强度值,下调P-GP和mdr1mRNA表达。结论:APS可增强H22/ADM化疗敏感性,机制可能与降低P-GP外排功能,下调P-GP和mdr1mRNA表达有关。
OBJECTIVE To explore the enhanced chemotherapeutic effects and relevant mechanism of Astragalus polysaccharide（APS） in vitro.METHODS After H22/ADM were incubated by Astragalus polysaccharide in combination with chemotherapy drugs,the chemotherapeutic drug sensitivity,P-GP function,P-GP and MDR1 mRNA expression were detected by MTT assay,flow cytometry,Western blot and quantitative RT-PCR.RESULTS At final concentration range of 0.8-500 μg·mL-1,APS could reduce the IC50value of ADM,5-Fu,DDP and VP-16 respectively,increase the fluorescence intensity values and down-regulate P-GP and MDR1 mRNA expression.CONCLUSION APS could enhance chemotherapy sensitivity,which may be related to decrease P-GP efflux pump activity and down-regulate P-GP and MDR1 mRNA expression.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2012年第21期1699-1703,共5页
Chinese Journal of Hospital Pharmacy
